Mechanism of restoration of immune responses of patients with chronic hepatitis B during lamivudine therapy: Increased antigen processing and presentation by dendritic cells

Journal of Viral Hepatitis

Volumn 18, Issue 3, 2011, Pages 200-205

  Akbar, S M F ^a,b   Horiike, N ^b   Chen, S ^b   Michitaka, K ^b   Abe, M ^b   Hiasa, Y ^b   Matsuura, B ^b   Onji, M ^b  

^a Shinagawa ku   (Japan)

^b EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

chronic hepatitis B; dendritic cells; immune restoration; lamivudine

Indexed keywords

GAMMA INTERFERON; HEPATITIS B SURFACE ANTIGEN; INTERLEUKIN 12; LAMIVUDINE;

ADULT; AGED; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ARTICLE; CELL FUNCTION; CELL ISOLATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; HEPATITIS B; HUMAN; HUMAN CELL; IMMUNE RESPONSE; LEUKOCYTE; LYMPHOCYTE PROLIFERATION; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; T LYMPHOCYTE;

ADULT; AGED; ANTIGEN PRESENTATION; CELL GROWTH PROCESSES; DENDRITIC CELLS; DNA, VIRAL; FEMALE; FLOW CYTOMETRY; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; IMMUNITY, INNATE; IMMUNOPHENOTYPING; LAMIVUDINE; LYMPHOCYTE CULTURE TEST, MIXED; MALE; MIDDLE AGED; REVERSE TRANSCRIPTASE INHIBITORS; STATISTICS, NONPARAMETRIC; YOUNG ADULT;

EID: 79951481332     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2010.01300.x     Document Type: Article

References (22)

1. Ganem D, Prince AM,. Hepatitis B virus infection-natural history and clinical consequences. N Engl J Med 2004; 350: 1118-1129. (Pubitemid 38298992)
2. Perz JF, Armstrong GL, Farrington LA, Huttin YJF, Bell BP,. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006; 45: 529-538. (Pubitemid 44307383)
3. Lok AS, McMohan BJ,. Chronic hepatitis B. Hepatology 2007; 45: 507-539. (Pubitemid 46374607)
4. Boni C, Bertoletti A, Penna A, et al. Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B. J Clin Invest 1998; 102: 968-975. (Pubitemid 28419565)
5. Boni C, Penna A, Ogg GS, et al. Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: new perspectives for immune therapy. Hepatology 2001; 33: 963-971. (Pubitemid 32246646)
6. Cooksley H, Chokshi S, Maayan Y, et al. Hepatitis B virus e antigen loss during adefovir dipivoxil therapy is associated with enhanced virus-specific CD4+ T-cell reactivity. Antimicrob Agents Chemother 2008; 52: 312-320.
7. You J, Sriplung H, Geater A, et al. Impact of viral replication inhibition by entecavir on peripheral T lymphocyte subpopulations in chronic hepatitis B patients. BMC Infect Dis 2008; 8: 123. ().
8. Evans A, Riva A, Cooksley H, et al. Programmed death 1 expression during antiviral treatment of chronic hepatitis B: impact of hepatitis B e-antigen seroconversion. Hepatology 2008; 48: 759-769.
9. Steinman RM,. Dendritic cells: understanding immunogenicity. Eur J Immunol 2007; 37 (Suppl 1): S53-S60. (Pubitemid 350131268)
10. Onji M, Akbar SM,. Dendritic Cells in Clinics. Tokyo: Springer, 2008.
11. Banchereau J, Paluka K,. Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol 2005; 3: 296-306. (Pubitemid 40516155)
12. Mellman I, Steinman RM,. Dendritic cells: specialized and regulated antigen processing machines. Cell 2001; 106: 255-258. (Pubitemid 32772607)
13. Op den Brouw ML, Binda RS, van Roosmalen MH, et al. Hepatitis B virus surface antigen impairs myeloid dendritic cell function: a possible immune escape mechanism of hepatitis B virus. Immunology 2009; 126: 280-289.
14. Hasebe A, Akbar SM, Furukawa S, Horiike N, Onji M,. Impaired functional capacities of liver dendritic cells from murine hepatitis B virus (HBV) carriers: relevance to low HBV-specific immune responses. Clin Exp Immunol 2005; 139: 35-42. (Pubitemid 40066126)
15. Duan XZ, Wang M, Li HW, Zhuang H, Xu D, Wang FS,. Decreased frequency and function of circulating plasmocytoid dendritic cells (pDC) in hepatitis B virus infected humans. J Clin Immunol 2004; 24: 637-646. (Pubitemid 40933115)
16. Wertheimer AM, Bakke A, Rosen HR,. Direct enumeration and functional assessment of circulating dendritic cells in patients with liver disease. Hepatology 2004; 40: 335-345. (Pubitemid 39062851)
17. Tsubouchi E, Akbar SM, Murakami H, Horiike N, Onji M,. Isolation and functional analysis of circulating dendritic cells from hepatitis C virus (HCV) RNA-positive and HCV RNA-negative patients with chronic hepatitis C: role of antiviral therapy. Clin Exp Immunol 2004; 137: 417-423. (Pubitemid 39013090)
18. Akbar SM, Furukawa S, Yoshida O, Hiasa Y, Horiike N, Onji M,. Induction of anti-HBs in HB vaccine nonresponders in vivo by hepatitis B surface antigen-pulsed blood dendritic cells. J Hepatol 2007; 47: 60-66. (Pubitemid 46817695)
19. Janssen HL, van Zonneveld M, Senturk H, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005; 365: 123-129. (Pubitemid 40091801)
20. Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005; 352: 2682-2695. (Pubitemid 41007823)
21. Marcellin P, Lau GK, Bonino F, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004; 351: 1206-1217. (Pubitemid 39296307)
22. Vandepapelière P, Lau GK, Leroux-Roels G, et al. Therapeutic vaccination of chronic hepatitis B patients with virus suppression by antiviral therapy: a randomized, controlled study of co-administration of HBsAg/AS02 candidate vaccine and lamivudine. Vaccine 2007; 25: 8585-8597. (Pubitemid 350192039)